A Phase 3 Trial of Brepocitinib in Dermatomyositis

By afschroeder • March 31, 2026

Vleugels RA, Paik JJ, Bauer Ventura I, Mangold AR, Gandiga PC, Haemel A, Chinoy H, Hussain YM, Sivakumar K, Zoltan G, Lee EB, Bozan F, Hsu CY, Femia A, Dimachkie MM, Min MS, Mozaffar T, Charles-Schoeman C, Fernandez DR, Onajin O, Marques R, Marder G, Ernste F, Schiopu E, Sluzevich J, Pearson D, Lindsey S, Luggen M, Bubb MR, Boh E, Maganti R, Heinlen L, Shaw KS, Cascino MD, Mudd PN Jr, Vencovsky J, Fernandez AP, Fiorentino D, Christopher-Stine L, Werth VP, Aggarwal R; VALOR Investigators. A Phase 3 Trial of Brepocitinib in Dermatomyositis. N Engl J Med. 2026 Mar 28. doi: 10.1056/NEJMoa2503531. Epub ahead of print. PMID: 41910335.

Tags: Publications, Rheumatology

What are the true medical concerns facing unsheltered homeless adults?

Kuhn R, Chien J, Shannon EM, Saluja S, Righi G, Damra M, King CM, Gelberg L, Henwood BF. What are the true medical concerns facing[...]

Variation in supplemental benefits in Medicare Advantage affinity plans, 2022-2024

Dorneo A, Oronce CIA, Garrido MM, Figueroa JF, Nguyen KH. Variation in supplemental benefits in Medicare Advantage affinity plans, 2022-2024. Health Aff Sch. 2026 Mar[...]

A randomized controlled trial of pulsed field ablation vs antiarrhythmic therapy as a first-line treatment for persistent atrial fibrillation: The AVANT GUARD trial rationale and design

Wazni OM, Chun KJ, Amin A, Anic A, Ajijola OA, Gibson DN, Mansour M, Makati K, Chrispin J, Duytschaever M, Nair DG, Piccini JP, Natale[...]